Stock Researching

Gilead Sciences' Tybost Approved By European Commission

Stock Researching
Publish date: Thu, 26 Sep 2013, 09:30 AM
Stock Researching
0 254,258
Stockresearching is a blog designed to help the independent investor create new ideas and receive valuable informed information.
Following Message

From Liston Street Pulse:

Gilead Sciences Inc. (GILD) said on Wednesday that the European Commission has approved its once-a-day drug Tybost. Tybost is a pharmacokinetic enhancer; meant to improve blood levels of certain HIV treatments. The drug is seen boosting agent for the HIV protease inhibitors (atazanavir 300 mg once daily and darunavir 800 […]

The post Gilead Sciences' Tybost Approved By European Commission appeared first on Liston Street Pulse.

More articles on Stock Researching
Visa Inc: Inside the Numbers 2016 $V

Created by Stock Researching | Dec 17, 2016

Enbridge Inc: 2016 Fundamental Analysis WACC, Cost of Debt and Cost of Equity $ENB

Created by Stock Researching | Dec 13, 2016

Apple Inc: DCF Calculation Apple Inc. $AAPL

Created by Stock Researching | Dec 10, 2016

Apple Inc: Fundamental Analysis WACC, Cost of Debt and Cost of Equity $AAPL

Created by Stock Researching | Dec 04, 2016

Visa Inc: DCF Calculation Visa Inc. $V

Created by Stock Researching | Dec 03, 2016

Visa Inc: Fundamental Analysis WACC, Cost of Debt and Cost of Equity $V

Created by Stock Researching | Dec 02, 2016

Telus Corp. Cost of Debt, CAPM, WACC and Valuation $TU, $T.TO

Created by Stock Researching | Nov 19, 2016

Assessing Canadian Telecom Exposure, $BCE is worth a look

Created by Stock Researching | Nov 10, 2016

J&J Current Valuation. Is This The Time To Buy? $JNJ

Created by Stock Researching | Sep 17, 2016

$UPS Deriving Value From E-Commerce Growth And Lower Energy Prices

Created by Stock Researching | Oct 05, 2015

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment